The European Medicines Agency believes that there may be a link between the vaccine and special cases of the disease.
The case is being updated.
– After a long discussion, we concluded that these rare blood clot cases are very rare side effects of the vaccine, said Sabine Straus of the European Commission on Side Effects.
The European Medicines Agency has now concluded that abnormal blood clots should be classified as an abnormal side effect of the AstraZeneca vaccine.
At the same time, they believe that the benefits of vaccines outweigh the risks.
Therefore, the vaccine is still approved for use in Europe, and it is up to countries to consider how it should be used.
Norway, like Denmark, has temporarily stopped using this vaccine. Sweden, Germany and Finland are the countries that choose to continue to use it among the elderly.
Wrote on wednesday afternoon
British Broadcasting Corporation British authorities have decided not to vaccinate people between 18 and 29 years of age.
NIPH announced that it will conduct a new evaluation of the AstraZeneca vaccine on April 15.
When the EMA evaluated the vaccine last time, they chose to include warnings about special disease cases in the drug review of the vaccine, but they believed that the relevant literature was not enough to include it on the side effects list. This led to an objection from the representative of the Norwegian Drug Administration.
Therefore, EMA now chooses to list side effects as possible side effects.
EMA reminds healthcare professionals and people receiving the vaccine to be aware of the possibility of a very small number of thrombosis with low platelet levels within 2 weeks after vaccination. To date, most of the reported cases have occurred in women under 60 years of age within 2 weeks of vaccination.
Their hypothesis about what happened is similar to the hypothesis put forward by Norwegian experts in mid-March that the patient’s immune response caused the disease.